Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Daiichi Sankyo
Harvard Business School
Julphar
Accenture
QuintilesIMS
Argus Health
Medtronic
Express Scripts

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,420,592

« Back to Dashboard

Which drugs does patent 8,420,592 protect, and when does it expire?

Patent 8,420,592 protects ORBACTIV and is included in one NDA.

This patent has eighteen patent family members in fifteen countries.
Summary for Patent: 8,420,592
Title:Methods of treatment using single doses of oritavancin
Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.
Inventor(s): Lehoux; Dario (Terrebonne, CA), Parr; Thomas R. (Indianapolis, IN), Moeck; Gregory (St. Laurent, CA), Etienne; Pierre (Montreal, CA)
Assignee: The Medicines Company (Parsippany, NJ)
Application Number:13/060,811
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 8,420,592

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,420,592

PCT Information
PCT FiledAugust 29, 2009PCT Application Number:PCT/US2009/055466
PCT Publication Date:March 04, 2010PCT Publication Number: WO2010/025438

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Fuji
US Army
Express Scripts
McKinsey
Cipla
Fish and Richardson
Teva
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.